Logo image of TOVX

THERIVA BIOLOGICS INC (TOVX) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:TOVX - US87164U5083 - Common Stock

0.2426 USD
+0 (+0.66%)
Last: 1/6/2026, 8:04:00 PM
0.25 USD
+0.01 (+3.05%)
After Hours: 1/6/2026, 8:04:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TOVX. TOVX was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of TOVX have multiple concerns. TOVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TOVX has reported negative net income.
TOVX had a negative operating cash flow in the past year.
TOVX had negative earnings in each of the past 5 years.
TOVX had a negative operating cash flow in each of the past 5 years.
TOVX Yearly Net Income VS EBIT VS OCF VS FCFTOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -82.49%, TOVX is doing worse than 68.87% of the companies in the same industry.
The Return On Equity of TOVX (-278.22%) is worse than 71.89% of its industry peers.
Industry RankSector Rank
ROA -82.49%
ROE -278.22%
ROIC N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
TOVX Yearly ROA, ROE, ROICTOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

TOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TOVX Yearly Profit, Operating, Gross MarginsTOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

TOVX has less shares outstanding than it did 1 year ago.
TOVX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TOVX has a worse debt to assets ratio.
TOVX Yearly Shares OutstandingTOVX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
TOVX Yearly Total Debt VS Total AssetsTOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

TOVX has an Altman-Z score of -16.00. This is a bad value and indicates that TOVX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.00, TOVX is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
TOVX has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TOVX (0.15) is worse than 63.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -16
ROIC/WACCN/A
WACCN/A
TOVX Yearly LT Debt VS Equity VS FCFTOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.19 indicates that TOVX should not have too much problems paying its short term obligations.
TOVX has a Current ratio of 1.19. This is amonst the worse of the industry: TOVX underperforms 84.72% of its industry peers.
A Quick Ratio of 1.19 indicates that TOVX should not have too much problems paying its short term obligations.
TOVX has a worse Quick ratio (1.19) than 83.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 1.19
TOVX Yearly Current Assets VS Current LiabilitesTOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

TOVX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.87%.
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.10% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.55%
EPS Next 2Y36.8%
EPS Next 3Y24.87%
EPS Next 5Y18.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TOVX Yearly Revenue VS EstimatesTOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M
TOVX Yearly EPS VS EstimatesTOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1K -2K -3K -4K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOVX Price Earnings VS Forward Price EarningsTOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOVX Per share dataTOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as TOVX's earnings are expected to grow with 24.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.8%
EPS Next 3Y24.87%

More info and screens

0

5. Dividend

5.1 Amount

TOVX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (1/6/2026, 8:04:00 PM)

After market: 0.25 +0.01 (+3.05%)

0.2426

+0 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners1.34%
Inst Owner Change0%
Ins Owners0.11%
Ins Owner Change0%
Market Cap8.19M
Revenue(TTM)N/A
Net Income(TTM)-29.55M
Analysts80
Price Target7.14 (2843.12%)
Short Float %15.36%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.33%
Min EPS beat(2)38.93%
Max EPS beat(2)63.73%
EPS beat(4)3
Avg EPS beat(4)36.25%
Min EPS beat(4)-6.82%
Max EPS beat(4)63.73%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)33.15%
EPS NY rev (3m)33.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.87
EYN/A
EPS(NY)-3.76
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS0.31
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.49%
ROE -278.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.16%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 1.19
Altman-Z -16
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)94.56%
Cap/Depr(5y)59.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.39%
EPS Next Y16.55%
EPS Next 2Y36.8%
EPS Next 3Y24.87%
EPS Next 5Y18.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.46%
OCF growth 3YN/A
OCF growth 5YN/A

THERIVA BIOLOGICS INC / TOVX FAQ

What is the ChartMill fundamental rating of THERIVA BIOLOGICS INC (TOVX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to TOVX.


What is the valuation status for TOVX stock?

ChartMill assigns a valuation rating of 1 / 10 to THERIVA BIOLOGICS INC (TOVX). This can be considered as Overvalued.


How profitable is THERIVA BIOLOGICS INC (TOVX) stock?

THERIVA BIOLOGICS INC (TOVX) has a profitability rating of 0 / 10.


How financially healthy is THERIVA BIOLOGICS INC?

The financial health rating of THERIVA BIOLOGICS INC (TOVX) is 2 / 10.